Compare GSK plc (GSK) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roblox Corp — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while Roblox Corp trades at $55.83 (market cap $40.86B). The key difference: GSK plc is far larger — about 2.5× Roblox Corp's market cap, and GSK plc pays a 3.49% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| GSK | RBLX | |
|---|---|---|
Market Cap | $101.34B | $40.86B |
Sector | Health | Media |
52-Week High | $61.18 | $141.56 |
52-Week Low | $36.20 | $41.30 |
Enterprise Value | $121.95B | $39.45B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Roblox (RBLX) trades at $54.47, down 1.12% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The company shows strong revenue growth, reaching $4.89B in 2025, but continues to report significant net losses (-$1.07B). Analyst consensus is positive with a $59.62 price target, though multiple class action lawsuits create near-term legal overhang. Operating cash flow improved to $1.8B in 2025, supporting ongoing platform investments.
RBLX presents a growth-at-a-value story with robust user monetization potential offset by persistent profitability challenges. The stock offers upside to analyst targets but faces execution risks from legal proceedings and the need to translate revenue growth into sustainable earnings. Investor focus remains on Q3 2026 DAU recovery and margin improvement prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
